H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on ImmunityBio (IBRX – Research Report) today and set a price target of $8.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight ImmunityBio’s innovative approach to treating lymphopenia, a condition associated with early mortality in cancer patients. The company’s Cancer BioShield platform, which includes ANKTIVA and PD-L1 t-haNK CAR-NK cells, has received significant regulatory milestones such as RMAT designation and Expanded Access authorization from the FDA. These approvals underscore the potential of ImmunityBio’s therapies to address immune collapse in challenging cancer cases.
Furthermore, clinical data presented at ASCO 2025 demonstrated a clear survival benefit for patients with metastatic pancreatic cancer treated with this platform. The Phase 2 QUILT-88 trial showed that patients achieving immune recovery had significantly improved overall survival rates. Additionally, a case report highlighted the durable disease control achieved with ANKTIVA in a patient with metastatic pancreatic cancer, emphasizing its role in reversing lymphopenia and enhancing anti-tumor responses. These promising results validate ImmunityBio’s dual mechanism approach and support its potential for earlier intervention in cancer treatment.
In another report released on May 20, Piper Sandler also upgraded the stock to a Buy with a $5.00 price target.